<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38919940</PMID><DateRevised><Year>2024</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Post-COVID-19 condition: a sex-based analysis of clinical and laboratory trends.</ArticleTitle><Pagination><StartPage>1376030</StartPage><MedlinePgn>1376030</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1376030</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1376030</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIM" NlmCategory="UNASSIGNED">Post-COVID-19 condition (PCC) encompasses long-lasting symptoms in individuals with COVID-19 and is estimated to affect between 31-67% of patients, with women being more commonly affected. No definitive biomarkers have emerged in the acute stage that can help predict the onset of PCC, therefore we aimed at describing sex-disaggregated data of PCC patients from a local cohort and explore potential acute predictors of PCC and neurologic PCC.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A local cohort of consecutive patients admitted with COVID-19 diagnosis between June 2020 and July 2021 were registered, and clinical and laboratory data were recorded. Only those &lt;65&#x2009;years, discharged alive and followed up at 6 and 12&#x2009;months after admission were considered in these analyses. Multivariable logistic regression analysis was performed to explore variables associated with PCC (STATA v 18.0).</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">From 130 patients in the cohort, 104 were contacted: 30% were women, median age of 42&#x2009;years. At 6&#x2009;months, 71 (68%) reported PCC symptoms. Women exhibited a higher prevalence of any PCC symptom (87 vs. 60%, <i>p</i>&#x2009;=&#x2009;0.007), lower ferritin (<i>p</i>&#x2009;=&#x2009;0.001) and procalcitonin (<i>p</i>&#x2009;=&#x2009;0.021) and higher TNF levels (<i>p</i>&#x2009;=&#x2009;0.042) in the acute phase compared to men. Being women was independently associated to 7.60 (95% CI 1.27-45.18, <i>p</i>&#x2009;=&#x2009;0.026) higher risk for PCC. Moreover, women had lower return to normal activities 6 and 12&#x2009;months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Our findings highlight the lasting impact of COVID-19, particularly in young women, emphasising the need for tailored post-COVID care. The lower ferritin levels in women are an intriguing observation, warranting further research. The study argues for comprehensive strategies that address sex-specific challenges in recovery from COVID-19.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 Delfino, Poli, Vial, Vial, Mart&#xed;nez, Riviotta, Arbat, Mac-Guire, Hoppe, Carvajal and Mu&#xf1;oz Venturelli.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delfino</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Estudios Cl&#xed;nicos, Instituto de Ciencias e Innovaci&#xf3;n en Medicina (ICIM), Facultad de Medicina Cl&#xed;nica Alemana Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poli</LastName><ForeName>M Cecilia</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Cl&#xed;nica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Inmunogen&#xe9;tica e Inmunolog&#xed;a Traslacional, Instituto de Ciencias e Innovaci&#xf3;n en Medicina, Facultad de Medicina, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unidad de Inmunolog&#xed;a y Reumatolog&#xed;a, Hospital Roberto del R&#xed;o, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vial</LastName><ForeName>Cecilia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Cl&#xed;nica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Hantavirus y Zoonosis, Instituto de Ciencias e Innovaci&#xf3;n en Medicina, Facultad de Medicina, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vial</LastName><ForeName>Pablo A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Cl&#xed;nica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Hantavirus y Zoonosis, Instituto de Ciencias e Innovaci&#xf3;n en Medicina, Facultad de Medicina, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departamento de Enfermedades Cardiovasculares, Pontificia Universidad Cat&#xf3;lica de Chile, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riviotta</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centro de Estudios Cl&#xed;nicos, Instituto de Ciencias e Innovaci&#xf3;n en Medicina (ICIM), Facultad de Medicina Cl&#xed;nica Alemana Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arbat</LastName><ForeName>Catalina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Cl&#xed;nica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mac-Guire</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Cl&#xed;nica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoppe</LastName><ForeName>Josefina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Facultad de Medicina Cl&#xed;nica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvajal</LastName><ForeName>Crist&#xf3;bal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centro de Inform&#xe1;tica Biom&#xe9;dica, Instituto de Ciencias e Innovaci&#xf3;n en Medicina (ICIM), Facultad de Medicina Cl&#xed;nica Alemana-Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mu&#xf1;oz Venturelli</LastName><ForeName>Paula</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centro de Estudios Cl&#xed;nicos, Instituto de Ciencias e Innovaci&#xf3;n en Medicina (ICIM), Facultad de Medicina Cl&#xed;nica Alemana Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Neurolog&#xed;a, Departamento de Neurolog&#xed;a y Psiquiatr&#xed;a, Cl&#xed;nica Alemana de Santiago, Facultad de Medicina Cl&#xed;nica Alemana-Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neurologic long-COVID-19</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword><Keyword MajorTopicYN="N">sex-disaggregated</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>26</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38919940</ArticleId><ArticleId IdType="pmc">PMC11198115</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1376030</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coronavirus disease (COVID-19) , Available at: https://www.who.int/news-room/fact-sheets/detail/coronavirus-disease-(covid-19) (Accessed September 26, 2023).</Citation></Reference><Reference><Citation>Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV, WHO Clinical Case Definition Working Group on Post-COVID-19 Condition . A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. (2022) 22:e102&#x2013;7. doi: 10.1016/S1473-3099(21)00703-9, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. . Short-term and long-term rates of Postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open. (2021) 4:e2128568. doi: 10.1001/jamanetworkopen.2021.28568, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.28568</ArticleId><ArticleId IdType="pmc">PMC8515212</ArticleId><ArticleId IdType="pubmed">34643720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari AJ, Santomauro DF, Aali A, Abate YH, Abbafati C, Abbastabar H, et al. . Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990&#x2013;2021: a systematic analysis for the global burden of disease study 2021. Lancet. (2024) 403:2133&#x2013;61. doi: 10.1016/S0140-6736(24)00757-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00757-8</ArticleId><ArticleId IdType="pmc">PMC11122111</ArticleId><ArticleId IdType="pubmed">38642570</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A, Cristillo V, Cotti Piccinelli S, Zoppi N, Bonzi G, Sattin D, et al. . Long-term neurological manifestations of COVID-19: prevalence and predictive factors. Neurol Sci. (2021) 42:4903&#x2013;7. doi: 10.1007/s10072-021-05586-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-021-05586-4</ArticleId><ArticleId IdType="pmc">PMC8439956</ArticleId><ArticleId IdType="pubmed">34523082</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjun MC, Singh AK, Pal D, Das K, Venkateshan M, Mishra B, et al. . Characteristics and predictors of long COVID among diagnosed cases of COVID-19. PLoS One. (2022) 17:e0278825. doi: 10.1371/journal.pone.0278825, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0278825</ArticleId><ArticleId IdType="pmc">PMC9767341</ArticleId><ArticleId IdType="pubmed">36538532</ArticleId></ArticleIdList></Reference><Reference><Citation>Low RN, Low RJ, Akrami A. A review of cytokine-based pathophysiology of long COVID symptoms. Front Med. (2023) 10:1011936. doi: 10.3389/fmed.2023.1011936, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1011936</ArticleId><ArticleId IdType="pmc">PMC10103649</ArticleId><ArticleId IdType="pubmed">37064029</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock D, Latz E, Morgan D, Brown R. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther. (2020) 12:69. doi: 10.1186/s13195-020-00640-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-020-00640-3</ArticleId><ArticleId IdType="pmc">PMC7271826</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Berg DF, Te Velde AA. Severe COVID-19: NLRP3 Inflammasome dysregulated. Front Immunol. (2020) 11:1580. doi: 10.3389/fimmu.2020.01580, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01580</ArticleId><ArticleId IdType="pmc">PMC7332883</ArticleId><ArticleId IdType="pubmed">32670297</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Di B, Xu L. The NLRP3 inflammasome and COVID-19: activation, pathogenesis and therapeutic strategies. Cytokine Growth Factor Rev. (2021) 61:2&#x2013;15. doi: 10.1016/j.cytogfr.2021.06.002, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8233448</ArticleId><ArticleId IdType="pubmed">34183243</ArticleId></ArticleIdList></Reference><Reference><Citation>Abulafia DP, de Rivero Vaccari JP, Lozano JD, Lotocki G, Keane RW, Dietrich WD. Inhibition of the Inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice. J Cereb Blood Flow Metab. (2009) 29:534&#x2013;44. doi: 10.1038/jcbfm.2008.143, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.2008.143</ArticleId><ArticleId IdType="pubmed">19066616</ArticleId></ArticleIdList></Reference><Reference><Citation>Schunk SJ, Kleber ME, M&#xe4;rz W, Pang S, Zewinger S, Triem S, et al. . Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. Eur Heart J. (2021) 42:1742&#x2013;56. doi: 10.1093/eurheartj/ehab107, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehab107</ArticleId><ArticleId IdType="pmc">PMC8244638</ArticleId><ArticleId IdType="pubmed">33748830</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustin M, Heyn F, Ullrich S, Sandaradura de Silva U, Albert MC, Linne V, et al. . Immunological fingerprint in coronavirus disease-19 convalescents with and without post-COVID syndrome. Front Med. (2023) 10:1129288. doi: 10.3389/fmed.2023.1129288, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1129288</ArticleId><ArticleId IdType="pmc">PMC10165999</ArticleId><ArticleId IdType="pubmed">37168268</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xf6;ller M, Borg K, Janson C, Lerm M, Normark J, Niward K. Cognitive dysfunction in post-COVID-19 condition: mechanisms, management, and rehabilitation. J Intern Med. (2023) 294:563&#x2013;81. doi: 10.1111/joim.13720, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13720</ArticleId><ArticleId IdType="pubmed">37766515</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, Barbanotti D, Castoldi R, Mul&#xe8; G, et al. . Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. (2022) 28:611.e9&#x2013;611.e16. doi: 10.1016/j.cmi.2021.11.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Granath F, Bruchfeld J, Askling J, Sj&#xf6;holm D, Fored M, et al. . Post COVID-19 condition diagnosis: a population-based cohort study of occurrence, associated factors, and healthcare use by severity of acute infection. J Intern Med. (2023) 293:246&#x2013;58. doi: 10.1111/joim.13584, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13584</ArticleId><ArticleId IdType="pmc">PMC9877994</ArticleId><ArticleId IdType="pubmed">36478477</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. . Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. (2022) 67:172&#x2013;81. doi: 10.1016/j.jcrc.2021.09.023, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2021.09.023</ArticleId><ArticleId IdType="pmc">PMC8604557</ArticleId><ArticleId IdType="pubmed">34808527</ArticleId></ArticleIdList></Reference><Reference><Citation>Alroomi M, Rajan R, Omar AA, Alsaber A, Pan J, Fatemi M, et al. . Ferritin level: a predictor of severity and mortality in hospitalized COVID-19 patients. Immun Inflamm Dis. (2021) 9:1648&#x2013;55. doi: 10.1002/iid3.517, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.517</ArticleId><ArticleId IdType="pmc">PMC8589386</ArticleId><ArticleId IdType="pubmed">34438471</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso-Dom&#xed;nguez J, Gallego-Rodr&#xed;guez M, Mart&#xed;nez-Barros I, Calder&#xf3;n-Cruz B, Leiro-Fern&#xe1;ndez V, P&#xe9;rez-Gonz&#xe1;lez A, et al. . High levels of IL-1&#x3b2;, TNF-&#x3b1; and MIP-1&#x3b1; one month after the onset of the acute SARS-CoV-2 infection, predictors of post COVID-19 in hospitalized patients. Microorganisms. (2023) 11:2396. doi: 10.3390/microorganisms11102396, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11102396</ArticleId><ArticleId IdType="pmc">PMC10609568</ArticleId><ArticleId IdType="pubmed">37894054</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima S, Ismail M, Ejaz T, Shah Z, Fatima S, Shahzaib M, et al. . Association between long COVID and vaccination: a 12-month follow-up study in a low-to middle-income country. PLoS One. (2023) 18:e0294780. doi: 10.1371/journal.pone.0294780, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0294780</ArticleId><ArticleId IdType="pmc">PMC10664948</ArticleId><ArticleId IdType="pubmed">37992084</ArticleId></ArticleIdList></Reference><Reference><Citation>Sansone D, Tassinari A, Valentinotti R, Kontogiannis D, Ronchese F, Centonze S, et al. . Persistence of symptoms 15 months since COVID-19 diagnosis: prevalence, risk factors and residual work ability. Life. (2022) 13:97. doi: 10.3390/life13010097, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13010097</ArticleId><ArticleId IdType="pmc">PMC9862952</ArticleId><ArticleId IdType="pubmed">36676046</ArticleId></ArticleIdList></Reference><Reference><Citation>Righi E, Mirandola M, Mazzaferri F, Razzaboni E, Zaffagnini A, Erbogasto A, et al. . Long-term patient-Centred follow-up in a prospective cohort of patients with COVID-19. Infect Dis Ther. (2021) 10:1579&#x2013;90. doi: 10.1007/s40121-021-00461-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-021-00461-3</ArticleId><ArticleId IdType="pmc">PMC8215633</ArticleId><ArticleId IdType="pubmed">34152573</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M, Palese A, Venturini M, de Martino M, Gerussi V, Graziano E, et al. . Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. (2021) 27:1507&#x2013;13. doi: 10.1016/j.cmi.2021.05.033, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.05.033</ArticleId><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, et al. . Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-Centre longitudinal study. Clin Microbiol Infect. (2021) 27:89&#x2013;95. doi: 10.1016/j.cmi.2020.09.023, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.023</ArticleId><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Comelli A, Viero G, Bettini G, Nobili A, Tettamanti M, Galbussera AA, et al. . Patient-reported symptoms and sequelae 12 months after COVID-19 in hospitalized adults: a multicenter long-term follow-up study. Front Med. (2022) 9:834354. doi: 10.3389/fmed.2022.834354, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.834354</ArticleId><ArticleId IdType="pmc">PMC8981315</ArticleId><ArticleId IdType="pubmed">35391879</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>